Permanent Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$225K Sell
859
-2,763
-76% -$708K 0.04% 20
2026
Q2
$911K Hold
3,622
– – 0.12% 58
2026
Q1
$772K Buy
3,622
+71
+2% +$15.7K 0.12% 60
2025
Q4
$811K Buy
3,551
+442
+14% +$101K 0.16% 63
2025
Q3
$720K Buy
+3,109
New +$633K 0.13% 69
2025
Q1
$651K Buy
3,109
+1,816
+140% +$353K 0.19% 27
2024
Q4
$230K Buy
+1,293
New +$238K 0.07% 60
2024
Q2
$577K Buy
+3,109
New +$515K 0.12% 76

Other funds holding ABBV

Permanent Capital Management's ABBV Position: Q3 2026 in Review

Permanent Capital Management reduced its AbbVie (ABBV) stake by 76% in Q3 2026, selling an estimated $708K and leaving 859 shares worth $225K. The position accounts for 0.04% of the portfolio, ranked #20.

Permanent Capital Management first reported a position in ABBV in Q2 2024 and has held it in 8 quarters since. The position peaked at $911K in Q2 2026. 4,285 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Permanent Capital Management held 859 shares of AbbVie worth $225K as of Q3 2026.
  • Permanent Capital Management sold 2,763 AbbVie shares in Q3 2026, an estimated $708K.
  • AbbVie made up 0.04% of Permanent Capital Management's portfolio in Q3 2026, its #20 holding.
  • Permanent Capital Management first reported a position in AbbVie in Q2 2024 and has held it in 8 quarters since.
  • Permanent Capital Management's AbbVie position peaked at $911K in Q2 2026.
  • 4,285 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Permanent Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.